Growth potential Mid-size CDMO with recent facility expansion and aseptic capability updates positions Upperton to pursue bigger pharmaceutical and biotech projects, especially in sterile manufacturing and complex dosage forms.

Innovation edge Strong emphasis on spray drying and advanced formulation technologies creates a differentiator for clients seeking scalable development and rapid transition to GMP/IMP manufacturing.

Strategic fit Multinational, diverse client base from startups to global players indicates opportunity to expand collaborations with mid-market Biotech and emerging pharma companies seeking dependable development and trial manufacturing partner.

Awards leverage Recent industry recognitions and Best Places to Work shortlist can be leveraged in outreach to potential customers highlighting reliability, culture, and service delivery excellence.

Geographic expansion New Nottingham sterile facility and broader Northern Europe footprint open doors for regional pharma projects, potentially reducing time-to-market and enabling local supply solutions for EU and UK partners.